Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
BHV-700 · 1 trial · 2 indications
Per-participant percentage reduction in patient-specific seizure surrogate rate in the treatment period relative to retrospective baseline.
Per-participant percentage reduction in seizure onset pattern rate in the treatment period relative to retrospective baseline.
Per-participant reduction in long episode rate during the treatment period relative to the retrospective baseline.
Per-participant reduction in saturation rate during the treatment period relative to the retrospective baseline, for those patients who have saturations.
| Arm | Type | Description |
|---|---|---|
| BHV-7000 | EXPERIMENTAL | Participants will receive up to 28 days of study drug and will be followed clinically until Day 56, making their total involvement in the study up to 84 days. The study follows an ABA treatment paradigm with (A) 90-day retrospective RNS baseline, (B) 4-week treatment period, and (A) 4-week withdrawal period. |
| Name | Type | Description |
|---|---|---|
| BHV-700 | DRUG | 75 mg daily for the 4-week treatment period (dose which may be adjusted based on tolerability) |
Inclusion Criteria: * Diagnosis of focal epilepsy as documented in the medical record. * Implanted at least 1 year ago with RNS. * RNS device actively recording intracranial EEG data. * Baseline RNS recordings show that the over 50% of detections represent epileptiform seizure onset patterns. * Pro...
BHV-700 is an investigational small molecule being developed for the treatment of epilepsy and seizures. It is currently in Phase 1 clinical development, with an active study evaluating its use in patients with epilepsy. The drug is not yet approved and remains under investigation.
BHV-700 targets the Kv7.2 and Kv7.3 potassium channels, which are involved in regulating neuronal excitability. By modulating these channels, the drug aims to reduce abnormal electrical activity in the brain that can lead to seizures. This mechanism is being studied for its potential in treating epilepsy.
BHV-700 is being developed by Biohaven Ltd., a biopharmaceutical company. The company is conducting clinical trials to evaluate the drug's safety and efficacy in patients with epilepsy. Biohaven is publicly traded under the ticker symbol BHVN.
BHV-700 is in Phase 1 clinical development. It is an investigational drug and has not been approved by regulatory authorities. The ongoing Phase 1 study is designed to assess the drug's safety, tolerability, and preliminary effects in patients with epilepsy and seizures.
BHV-700 is being studied in a Phase 1 clinical trial with the identifier NCT07125261. This trial, titled 'BHV-7000 Responsive Neurostimulation System (RNS) Study,' is active but not recruiting and is enrolling approximately 5 participants in the United States. The study is open to adults aged 18 years and older with epilepsy or seizures.
Yes, BHV-700 is also known as BHV-7000. The clinical trial NCT07125261 uses the name BHV-7000 in its title, referring to the same investigational drug. This alternative name may appear in trial registries and scientific literature related to the drug's development for epilepsy.